Core Insights - FactSet Research Systems reported accelerating growth in annual subscription value (ASV) for the fourth consecutive quarter, with organic ASV increasing by 6.7% to $2.45 billion [4] - The company achieved revenue of $611 million, reflecting a year-over-year increase of 7.1%, with 6.8% organic growth when excluding foreign exchange and M&A impacts [4] Regional Performance - In the Asia-Pacific region, organic ASV growth accelerated to 10% from 8% in the previous quarter, driven by increased demand from asset managers and hedge funds [1] - EMEA saw organic ASV growth of 4%, matching the previous quarter, with noted softness among asset owners due to pension reform in the Netherlands [2] - The Americas experienced a 7% organic ASV growth, up from 6% in the prior quarter, supported by strength in asset management and competitive displacements in banking [2] Client Activity and Retention - FactSet added 98 net new clients in the quarter, bringing the total to 9,101, with a user base exceeding 241,000, equating to a 10% annual growth rate [6] - Client retention remained strong at 91%, with ASV retention above 95% [6] AI Strategy and Product Development - The company emphasized AI as a demand driver and a means to enhance internal efficiency, with significant investments in technology and productivity initiatives [10][11] - FactSet's MCP server, launched in December, has over 120 active clients, and API call volumes have increased significantly [10] - Partnerships with Snowflake, Databricks, Anthropic, and OpenAI are aimed at enhancing cloud-based workflows and making FactSet datasets available in marketplaces [10] Financial Guidance and Capital Allocation - Based on first-half performance, FactSet raised its fiscal 2026 outlook for ASV, revenue, and EPS, with ASV growth now expected to be between $130 million to $160 million [11] - The company maintained its GAAP and adjusted operating margin guidance, with an accelerated pace of share repurchases, buying back approximately 652,000 shares for $163 million in Q2 [13] Management Commentary - CEO Sanoke Viswanathan highlighted improved commercial execution and productivity gains, positioning the company well for the second half of fiscal 2026 and beyond [14]

Core Insights - Ariel Focus Fund experienced a decline of -0.50% in Q4 2025, underperforming the S&P 500 and Russell 1000 Value indices, which gained +2.66% and +3.81% respectively, but achieved a +20.97% return over the full year [1] - The U.S. market environment was characterized by easing inflation, stable corporate earnings, and optimism around accommodative monetary policy, despite geopolitical risks and labor market softening [1] - The fund maintained a disciplined investment approach, selectively adding to positions without making exits during the quarter [1] Company Insights: Oracle Corporation - Oracle Corporation's stock had a one-month return of -6.85%, with shares trading between $118.86 and $345.72 over the last 52 weeks, closing at approximately $138.80 on March 30, 2026, with a market capitalization of about $399.20 billion [2] - Oracle underperformed in Q4 2025, missing revenue expectations but beating earnings due to gains from its divestiture of Ampere, with strong momentum in its cloud services [3] - Management reaffirmed a long-term growth outlook and increased investment in AI infrastructure, positioning Oracle as a key player in the AI platform shift, despite near-term margin pressures [3] - Current infrastructure investments are expected to lead to meaningful earnings growth over time, despite shares potentially remaining range-bound in the near term [3]

Group 1 - The company needs to convince Wall Street that it is still a media company according to Needham [1]

Core Viewpoint - A class action lawsuit has been filed against Atara Biotherapeutics, Inc. (ATRA) for securities fraud, affecting shareholders who acquired shares between May 20, 2024, and January 9, 2026, with a deadline for lead plaintiff motion set for May 22, 2026 [1]. Summary by Relevant Sections Company Background - Atara Biotherapeutics, Inc. is a biotechnology company focused on developing therapies for patients with serious diseases, including its Epstein-Barr treatment, tabelecleucel (EBVALLO) [4]. Events Leading to the Lawsuit - On January 16, 2025, Atara received a Complete Response Letter (CRL) from the FDA regarding its BLA for tabelecleucel, indicating that the application would not be approved in its current form, leading to a stock price drop of $5.33, or 40.5%, closing at $7.83 per share [4]. - On January 21, 2025, Atara announced a clinical hold on its active IND applications due to GMP compliance issues, resulting in a further stock price decline of $0.52, or 7.9%, to close at $6.05 per share [5]. - On January 12, 2026, Atara disclosed another CRL regarding the resubmitted tabelecleucel BLA, stating that the trial's design and conduct were inadequate for evidence of effectiveness, causing the stock price to fall by $7.79, or 56.99%, to close at $5.88 per share [6][7]. Allegations in the Lawsuit - The lawsuit alleges that Atara's management made materially false and misleading statements and failed to disclose significant adverse facts about the company's business and prospects, including: 1. Manufacturing issues and deficiencies in the ALLELE study that made FDA approval unlikely [7]. 2. Overstated regulatory prospects for tabelecleucel [7]. 3. Heightened risk of regulatory scrutiny due to manufacturing issues, jeopardizing ongoing clinical trials [7]. 4. Significant negative impacts on Atara's business and financial condition [7]. 5. Misleading positive statements regarding the company's operations and prospects [7].

Company Performance - FactSet Research Systems Inc. reported strong second-quarter results with sales of $611.02 million, exceeding analyst expectations of $604.51 million and reflecting a 7.1% year-over-year gain [3] - The company also reported adjusted earnings per share of $4.46, surpassing the street view of $4.37 [3] - FactSet raised its fiscal year 2026 adjusted EPS outlook to $17.25-$17.75 from a prior forecast of $16.90–$17.60, compared to the analyst consensus of $17.49 [4] Market Trends - U.S. stocks showed positive movement with the Nasdaq Composite gaining around 400 points, while the Dow rose 1.08% to 45,703.52, and the S&P 500 increased by 1.44% to 6,434.78 [1] - Communication services shares increased by 2.2%, while utilities stocks fell by 0.7% [2] - European shares also experienced gains, with the eurozone's STOXX 600 rising 0.9% and major indices in Spain, London, Germany, and France showing positive performance [6]

Market Overview - The U.S. stock market is experiencing a broad-based rally, with a significant drop in the CBOE Volatility Index (VIX) by nearly 9.5% to 27.71, indicating a "risk-on" sentiment among investors [1] - Major indexes are showing substantial daily gains as the first quarter of 2026 comes to a close, led by the technology sector [1] Major Market Indexes - The Nasdaq Composite (^IXIC) surged 388.86 points, or 1.87%, reaching 21,183.50, reflecting renewed interest in growth stocks and semiconductor leaders [2] - The S&P 500 (^GSPC) rose 89.23 points, or 1.41%, to 6,432.95, while the Dow Jones Industrial Average (^DJI) climbed 486.18 points, or 1.08%, currently trading at 45,702.32 [2] Small-Cap Stocks - The Russell 2000 (^RUT) increased by 1.61%, indicating a healthy market breadth that is not solely reliant on mega-cap technology stocks [3] Sector Performance - The Cannabis ETF (MSOS) was the top performer of the day, gaining 7.14%, driven by renewed legislative optimism [4] - The Biotech sector, represented by the SPDR S&P Biotech ETF (XBI), rose 5.51%, showcasing strong performance in speculative and growth-oriented areas [4] - Precious metals also showed strength, with Gold Futures (GC=F) increasing by 1.90% to $4,643.90 and the Silver ETF (SLV) up over 5% [4] Defensive Sectors - Defensive sectors lagged behind, with the Utilities Select Sector SPDR Fund (XLU) dropping 0.87% and Consumer Staples (XLP) down 0.66%, indicating a rotation out of "safe-haven" sectors into growth [5] Corporate News - Apellis Pharmaceuticals (APLS) saw its stock price skyrocket by 136.4% due to positive clinical developments, while Centessa Pharmaceuticals (CNTA) gained 45.2% [6] - Classover Holdings (KIDZ) surged 76.6% in early trading, while PepGen (PEPG) faced a sharp sell-off, losing 52.5% of its value [7] Earnings Reports - McCormick & Company (MKC) and FactSet Research Systems (FDS) reported quarterly results, with McCormick navigating a complex consumer environment and FactSet benefiting from high demand for financial data [8] Upcoming Earnings - Nike (NKE) is scheduled to release its Q3 2026 earnings, with analysts expecting an EPS of $0.29, which will be a critical indicator for global consumer discretionary spending [9] - Other notable companies reporting after hours include PVH Corp (PVH) and RH (RH) [9] - Investors will also receive updates from ConAgra Brands (CAG) and Cal-Maine Foods (CALM) before the market opens on April 1st, providing insights into food inflation and consumer health [10]

Company Performance - FactSet Research Systems Inc. reported strong second-quarter results with sales of $611.02 million, exceeding analyst expectations of $604.51 million and reflecting a 7.1% year-over-year gain [3] - The company also reported adjusted earnings per share of $4.46, surpassing the street view of $4.37 [3] Future Outlook - FactSet raised its fiscal year 2026 adjusted EPS forecast to $17.25-$17.75 from a prior range of $16.90–$17.60, compared to the analyst consensus of $17.49 [4] - The company also increased its sales outlook for FY2026 to $2.450 billion-$2.470 billion, up from the previous forecast of $2.423 billion–$2.448 billion, aligning closely with the consensus estimate of $2.449 billion [4]

Core Insights - Warren Buffett has stepped down as CEO of Berkshire Hathaway but remains actively involved in stock picking and investment discussions [1][2][3] - Greg Abel, Buffett's successor, is effectively managing the company and has been receiving inquiries from businesses looking to sell to Berkshire [2][3] Company Operations - Berkshire Hathaway operates as a decentralized network of autonomous subsidiaries, allowing Buffett to focus on investment opportunities rather than day-to-day management [3] - Abel is noted for his efficiency, covering more ground in a day than Buffett did even at his peak [3] Investment Strategy - Buffett continues to seek investment opportunities but finds it challenging to identify bargains in the current market conditions [4] - He has made a small purchase recently but did not provide details on the investment [4] Market Perspective - Buffett downplayed recent stock market corrections, stating they are minor compared to historical downturns [5] - He expressed admiration for Apple, estimating Berkshire's pretax income from its investment in the company to be over $100 billion [5] Philanthropic Activities - Buffett announced the revival of his charity lunch auction, with proceeds benefiting the Glide Foundation and Eat. Play. Learn. Foundation [5][6]

Core Viewpoint - A class action lawsuit has been filed against Pinterest, Inc. for securities fraud, affecting shareholders who acquired securities between February 7, 2025, and February 12, 2026, with a deadline for filing a lead plaintiff motion set for May 29, 2026 [1][2]. Financial Performance - On November 4, 2025, Pinterest reported third quarter 2025 financial results, with a revenue guidance midpoint of $1.325 billion, which was below the consensus expectation of $1.34 billion, leading to a stock price drop of $7.16, or 21.8%, to close at $25.75 per share on November 5, 2025 [3]. - On January 27, 2026, Pinterest announced a global restructuring plan affecting less than 15% of its workforce and anticipated incurring pre-tax restructuring charges of approximately $35 million to $45 million, resulting in a stock price decline of $2.49, or 9.6%, to close at $23.41 per share [4]. - On February 12, 2026, Pinterest released its fourth quarter 2025 financial results, reporting quarterly revenue of $1.32 billion, below the consensus estimate of $1.33 billion, and provided Q1 2026 revenue guidance of $951 million to $971 million, which was also below the consensus estimate of $980.6 million. Following this announcement, the stock price fell $3.12, or 16.8%, to close at $15.42 per share on February 13, 2026 [5][6]. Allegations in the Lawsuit - The lawsuit alleges that Pinterest made materially false and misleading statements and failed to disclose adverse facts about its business and operations, including: 1. Reduced revenues from advertising partners [6]. 2. Overstated ability to manage the impact of U.S. tariffs on its operations [6]. 3. Significant impact on advertising revenues leading to an imminent restructuring [6]. 4. Misleading positive statements regarding the Company's business and prospects [6].

Group 1 - Progress Software Corporation reported quarterly earnings of $1.60 per share, exceeding the analyst consensus estimate of $1.57 per share [1] - The company achieved quarterly sales of $247.799 million, surpassing the analyst consensus estimate of $246.401 million [1] Group 2 - Progress Software raised its FY2026 adjusted EPS guidance from a range of $5.82-$5.96 to $5.91-$6.03 and increased sales guidance from $986 million-$1 billion to $988 million-$1 billion [2] - Following the earnings announcement, Progress Software shares dipped 6.6% to trade at $26.38 [2] Group 3 - Oppenheimer analyst Ittai Kidron maintained an Outperform rating on Progress Software but lowered the price target from $70 to $57 [3] - Wedbush analyst Dan Ives also maintained an Outperform rating while cutting the price target from $65 to $45 [3] - Jefferies analyst Brent Thill maintained a Hold rating and reduced the price target from $45 to $34 [3]